SpicyIP Tidbit: Sun challengesJ&J

Sun Pharma has as of February 28th, 2008 decided to file a post grant opposition with the Mumbai patent office against a product patent extension granted to Johnson & Johnson’s Risperdal, used to treat psychological disorders and schizophrenia.

The patent, granted to Janssen Pharmaceutica, a group company of Johnson & Johnson, on July 20, 2007, with patent number 208191 relates to sustained-release particles of risperidone.

Sun Pharma has been marketing a generic version of this drug for the last few years in India under the brand name Sizodone and has moved against the patent on Risperdal, that is due to expire in the US on June 29, 2008. News reports state that the extension has only been sought in India and not in the US.

Leave a Reply

Your email address will not be published.